Publicaciones en colaboración con investigadoras/es de Hospital Clínico San Carlos de Madrid (44)

2024

  1. Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management

    Therapeutic Advances in Neurological Disorders, Vol. 17

  2. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  3. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

  4. Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology

    Journal of Alzheimer's disease : JAD, Vol. 102, Núm. 1, pp. 207-217

2023

  1. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

    PharmacoEconomics - Open, Vol. 7, Núm. 3, pp. 431-441

  2. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  3. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  4. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

2021

  1. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry

    PLoS ONE, Vol. 16, Núm. 10 October

  2. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)

    Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406

  3. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)

    Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442

2020

  1. Will neurological care change over the next 5 years due to the COVID-19 pandemic? Key informant consensus survey

    Neurologia, Vol. 35, Núm. 4, pp. 252-257

2019

  1. Recomendaciones de uso de cladribina comprimidos en la esclerosis múltiple recurrente

    Revista de neurologia, Vol. 69, Núm. s02, pp. 1-9

  2. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  3. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

2018

  1. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course 06 Biological Sciences 0604 Genetics 11 Medical and Health Sciences 1109 Neurosciences

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  2. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

2016

  1. Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

    PLoS ONE, Vol. 11, Núm. 8